MolNFT v1 · #34314 · protein
X-ray crystal structure analysis of bovine spleen cathepsin B-CA059 complex
2DC8: “X-ray crystal structure analysis of bovine spleen cathepsin B-CA059 complex”. X-ray diffraction, 2 ligands (59A, PO4), 2 pockets (best druggability 0.46). MolNFT v1 #34314 on GenesisL1: 3D structure, binding sites and pockets in…
- PDB
- 2DC8
- Type
- protein
- Length
- 251 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Cathepsin B
- EC
- 3.4.22.1
- Ligands
- 59A, PO4
- Pockets
- 2 · best druggability 0.46
Structure
x-ray diffraction · 1 distinct chain · 26% helix, 26% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Cathepsin B (EC 3.4.22.1) | protein | 251 | 26% helix, 26% strand | — |
Ligands and binding sites
- 59A · N-{[(2S,3S)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl}-L-isoleucine · ligand · chains A
- PO4 · Phosphate ion · ion · chains A
- GOL · Glycerol · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 186 | 0.46 | 0.75 | 29 | 59A |
| 2 | 52 | 0.25 | 0.73 | 15 | empty |
Modifications
Observed in the structure: 7 disulfide, 1 covalent (disulfide, covalent ligand).
Compared structures
- 2DC8 · X-ray crystal structure analysis of bovine spleen cathepsin B-CA059 complex · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Elsewhere: RCSB PDB 2DC8 · PDBe 2DC8
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.